Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Gastrin
Overview
Gastrin is an endogenous peptide hormone secreted by G-cells in the gastric antrum and duodenum, existing primarily as gastrin-17 and gastrin-34. It binds to the CCK-2 receptor on parietal and enterochromaffin-like cells, stimulating gastric acid secretion and promoting gastric mucosal growth.
Mechanism of Action
Therapeutic applications have focused on gastrin analogs for diagnostic purposes and investigation of gastrin immunotherapy for gastrin-dependent tumors. Dysregulation of gastrin secretion occurs in conditions such as Zollinger-Ellison syndrome and atrophic gastritis.
Research Summary & Key Findings
Pentagastrin, a synthetic gastrin analog, was historically used for diagnostic gastric acid secretion testing but has been largely replaced by other methods. Gastrin immunotherapy approaches targeting gastrin or the CCK-2 receptor have been explored in preclinical models of gastric and pancreatic cancers with limited clinical translation. No gastrin-based peptide therapeutic is currently in active clinical development for gastrointestinal indications.
Clinical Status
Gastrin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Gastrin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Gastrin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Gastrin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Gastrointestinal
Octreotide (Sandostatin)
FDA ApprovedA synthetic octapeptide analog of somatostatin with a substantially longer half-life (90 minutes IV, 6 hours subcutaneou...
View detailsLanreotide (Somatuline Depot)
FDA ApprovedA synthetic octapeptide analog of somatostatin with high affinity for SSTR2 and moderate affinity for SSTR5 receptors. L...
View detailsPasireotide (Signifor)
FDA ApprovedA multireceptor-targeted somatostatin analog with high binding affinity for SSTR1, SSTR2, SSTR3, and SSTR5, particularly...
View detailsPlecanatide (Trulance)
FDA ApprovedA synthetic 16-amino acid peptide structurally related to uroguanylin, an endogenous intestinal peptide that regulates f...
View detailsNo lawful pathway today
Gastrin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.